Skip to main content
Clinical Trials/NCT06929897
NCT06929897Enrolling By InvitationNot Applicable

Comparison of Pulmonary Vein Isolation Alone Versus Pulmonary Vein Isolation With Posterior Wall Isolation for Pulse-Field Ablation in Persistent Atrial Fibrillation: A Prospective Randomized Controlled Trial

Ewha Womans University Mokdong Hospital1 site in 1 country482 target enrollmentStarted: July 3, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
482
Locations
1
Primary Endpoint
Recurrence of atrial tachyarrhythmia

Study Overview

Brief Summary

To date, no optimal treatment has been established to improve outcomes in patients with persistent atrial fibrillation. The safety and efficacy of pulsed-field ablation (PFA) have been demonstrated in several studies, and its clinical application is expanding.

- In patients with persistent atrial fibrillation, can the addition of posterior wall isolation (PWI) following pulmonary vein isolation (PVI) using PFA reduce recurrence?

Participants will:

  • Undergo either PVI alone or PVI with additional left atrial posterior wall isolation (PWI)
  • Visit the clinic to assess for recurrence of atrial tachyarrhythmias

Detailed Description

Atrial fibrillation is a major cardiovascular disease, and catheter ablation has become an established rhythm-control strategy that provides superior outcomes compared with pharmacological therapy in patients with drug-refractory atrial fibrillation. Although the efficacy of pulmonary vein isolation (PVI) is well established in patients with paroxysmal atrial fibrillation, the effectiveness of additional ablation strategies beyond PVI remains uncertain in patients with persistent atrial fibrillation.

Several studies have suggested that left atrial posterior wall isolation (PWI) may help reduce recurrence; however, conventional thermal ablation techniques have been limited by technical challenges in achieving durable lesion formation. Pulsed field ablation (PFA) is a nonthermal ablation technology that creates selective myocardial lesions, enabling rapid and consistent lesion formation while minimizing injury to surrounding tissues.

This study aims to prospectively and randomly compare PVI alone using PFA with PVI followed by additional PWI in patients with persistent atrial fibrillation. By evaluating recurrence rates, procedure time, complications, atrial fibrillation burden, and patient satisfaction, this study seeks to identify the optimal ablation strategy for patients with persistent atrial fibrillation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients aged 20 to 80 years who are candidates for catheter ablation for persistent atrial fibrillation
  • •Patients eligible for catheter ablation according to existing clinical guidelines
  • •Those without clinically significant structural heart disease (e.g., severe mitral regurgitation)
  • •Those without contraindications to anticoagulation therapy

Exclusion Criteria

  • •Atrial fibrillation associated with severe congenital heart disease or structural heart disease
  • •Patients with contraindications to general anesthesia or sedation for the procedure
  • •History of prior cardiac surgery (e.g., Maze procedure, coronary artery bypass grafting)
  • •History of atrial fibrillation catheter ablation within the past 12 months
  • •Patients with severe left ventricular dysfunction (left ventricular ejection fraction <30%)
  • •Patients with active internal bleeding
  • •Patients with contraindications to anticoagulation therapy and antiarrhythmic drugs
  • •Valvular atrial fibrillation (e.g., mitral stenosis > grade 2, mechanical valve, prior mitral valve repair)
  • •Patients with severe comorbid conditions
  • •Patients with an expected survival of less than one year
  • •Patients with drug or alcohol addiction
  • •Pregnant or breastfeeding women
  • •Any other conditions deemed by the investigator to make the patient unsuitable for study participation

Arms & Interventions

Additional Left Atrial Posterior Wall Ablation Group

Active Comparator

Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo additional left atrial posterior wall isolation using pulsed field ablation. Before completion of the procedure, electrical isolation of both the pulmonary veins and the left atrial posterior wall will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

Intervention: Pulmonary Vein Isolation (Procedure)

Additional Left Atrial Posterior Wall Ablation Group

Active Comparator

Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo additional left atrial posterior wall isolation using pulsed field ablation. Before completion of the procedure, electrical isolation of both the pulmonary veins and the left atrial posterior wall will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

Intervention: Additional Left Atrial Posterior Wall Ablation (Procedure)

Pulmonary Vein Isolation (PVI) only Group

Placebo Comparator

Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo no additional left atrial posterior wall isolation. Before completion of the procedure, electrical isolation of the pulmonary veins will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

Intervention: Pulmonary Vein Isolation (Procedure)

Pulmonary Vein Isolation (PVI) only Group

Placebo Comparator

Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo no additional left atrial posterior wall isolation. Before completion of the procedure, electrical isolation of the pulmonary veins will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

Intervention: Non-PV trigger test (Procedure)

Outcomes

Primary Outcomes

Recurrence of atrial tachyarrhythmia

Time Frame: Within 12 months after the procedure, excluding the first 4-week blanking period

Freedom from documented AF/AT/AFL ≥30 seconds at 12 months post-procedure

Secondary Outcomes

  • Total procedure time(Periprocedural)
  • Peri-procedural complication(Within 12 months after the procedure)
  • Atrial fibrillation burden assessed by Holter ECG(Within 12 month from the time of enrollment)
  • Length of hospital stay(Within one year from the time of enrollment)
  • patient satisfaction(Within one year from the time of enrollment)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 4
Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial FibrillationAtrial Fibrillation
NCT02475642VZW Cardiovascular Research Center Aalst152
Active, not recruiting
Phase 1
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 100000004849
EUCTR2018-002103-33-DKAZ Sint-Jan Brugge-Oostende AV220
Active, not recruiting
Phase 1
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.
EUCTR2018-002103-33-ESAZ Sint-Jan Brugge-Oostende AV220
Active, not recruiting
Phase 1
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849
EUCTR2018-002103-33-FRAZ Sint-Jan Brugge-Oostende AV220
Active, not recruiting
Phase 1
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849
EUCTR2018-002103-33-ATAZ Sint-Jan Brugge-Oostende AV220